GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Brian Andrew Mitchell Sells 2,000 Shares

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Brian Andrew Mitchell sold 2,000 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $5.05, for a total transaction of $10,100.00. Following the transaction, the senior vice president now owns 198,747 shares of the company’s stock, valued at approximately $1,003,672.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

GNMK traded down $0.14 during trading on Tuesday, hitting $4.63. 468,091 shares of the company traded hands, compared to its average volume of 326,365. The firm has a market cap of $268.62 million, a P/E ratio of -5.08 and a beta of 1.15. The stock’s fifty day moving average is $5.22 and its 200 day moving average is $5.83. The company has a quick ratio of 2.11, a current ratio of 2.69 and a debt-to-equity ratio of 6.40. GenMark Diagnostics, Inc has a one year low of $4.47 and a one year high of $8.37.

GenMark Diagnostics (NASDAQ:GNMK) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $20.92 million for the quarter, compared to the consensus estimate of $20.66 million. GenMark Diagnostics had a negative return on equity of 239.16% and a negative net margin of 60.63%. On average, equities research analysts forecast that GenMark Diagnostics, Inc will post -0.81 EPS for the current fiscal year.

Several equities analysts recently weighed in on the stock. ValuEngine upgraded shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Thursday, December 26th. JPMorgan Chase & Co. lowered shares of GenMark Diagnostics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $11.00 to $7.00 in a research report on Wednesday, December 11th. Zacks Investment Research lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 8th. Finally, BidaskClub upgraded shares of GenMark Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $9.67.

Large investors have recently modified their holdings of the business. Bank of Montreal Can boosted its position in GenMark Diagnostics by 145.4% during the second quarter. Bank of Montreal Can now owns 7,687 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 4,554 shares during the period. Metropolitan Life Insurance Co NY boosted its position in GenMark Diagnostics by 15.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 18,942 shares of the medical equipment provider’s stock worth $115,000 after purchasing an additional 2,602 shares during the period. Susquehanna International Group LLP bought a new position in GenMark Diagnostics during the second quarter worth about $131,000. Commonwealth Equity Services LLC boosted its position in GenMark Diagnostics by 20.6% during the third quarter. Commonwealth Equity Services LLC now owns 21,700 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 3,700 shares during the period. Finally, Stifel Financial Corp bought a new position in GenMark Diagnostics during the third quarter worth about $131,000. Hedge funds and other institutional investors own 90.84% of the company’s stock.

About GenMark Diagnostics

GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.

Recommended Story: Understanding Analyst Recommendations

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.